SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing intense selling pressure, hitting 12-year lows as investor skepticism grows regarding the company's turnaround initiatives and ability to compete with surging athletic footwear rivals. The community is sharply divided, with some traders actively shorting the stock as a 'value trap' while others are aggressively buying the dip, banking on its iconic brand status, dividend yield, and potential for a long-term rebound.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is trending as investors debate the potential for a short squeeze ahead of upcoming earnings, fueled by aggressive short interest and conflicting reports on dilution risks. While some in the community express frustration over the company's lack of a confirmed earnings date and historical share price volatility, others are banking on the company's expansion into the sovereign AI infrastructure market as a primary catalyst for a turnaround.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is trending due to its recent confirmation of strong 2026 revenue expectations, bolstered by major five-year hosting agreements with Axe Compute valued over $500 million. Investors are actively debating the company's aggressive infrastructure expansion in the AI data center sector, weighing the significance of these large-scale contract wins against the potential for shareholder dilution and execution risks.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is experiencing heightened volatility and community debate as investors weigh the stock's significant decline against its deep-value valuation and incoming leadership transition. While some participants are actively accumulating shares in anticipation of a turnaround, others remain skeptical, pointing to increased competition and shifting consumer preferences as long-term headwinds.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet is trending following a strong fiscal quarter that featured double-line beats and raised guidance for the upcoming period, fueling investor enthusiasm about the company's role in the AI optical packaging and data center infrastructure buildout. Despite stellar results, community discussion reflects volatility concerns, with some traders debating whether the stock's premium valuation and recent price action represent a healthy consolidation or a potential setup for a short-term pullback.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is surging on significant investor enthusiasm following the FDA approval of its lead drug, Komzifti, with the community highlighting its best-in-class safety profile and once-daily dosing as key advantages over competitors. The conversation is heavily focused on the company's strong institutional backing, healthy cash reserves, and the potential for a transformative 2026 as it pushes into frontline AML indications and expands its solid tumor pipeline.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to a recent scientific conference update that de-risked the company's path toward a Q4 BLA submission for its prostate cancer therapy, CAN-2409. Community sentiment remains highly bullish, with active discussions focused on the company's strong institutional backing, potential acquisition appeal, and the significant addressable market for its novel viral immunotherapy platform.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is trending as investors react to the launch of its second-generation autonomous trucks, with the community actively debating the timing of commercial scaling and the impact of the company's deepening partnership ecosystem. Sentiment remains heavily focused on potential catalysts ahead of upcoming earnings, with long-term investors highlighting the technology's production readiness while others closely monitor short-selling activity and market volatility.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals is drawing significant attention as investors anticipate topline Phase 3 data for avexitide in post-bariatric hypoglycemia, a major potential commercial catalyst. The community is actively discussing the company's strong cash position, favorable institutional backing, and the broader clinical potential of its orphan drug pipeline.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as market participants weigh a major pending antitrust judgment against Google alongside a new partnership with Apple for a device-leasing program. Investors are actively discussing the stock's potential for a re-rating if these catalysts drive profitability or expansion, even as some traders caution about volatility and the impact of broader fintech sector performance on the share price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$OABI interesting options here this morning. news with LLY earlier this morning  
 
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly &amp; Company 
 
&quot; Eligible To Receive Up to $370M In R&amp;D and Commercial Milestone Payments&quot;

Andrew Lafayette

Samer Barakat

StockTwits Web

OmniAb Inc

 interesting options here this morning. news with LLY earlier this morning  
 
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company 
 
" Eligible To Receive Up to $370M In R&D and Commercial Milestone Payments"